GOTHENBURG, SWEDEN / ACCESSWIRE / September 19, 2024 / Today, XVIVO Perfusion AB (publ) (STO:XVIVO)(LSE:0RKL)(FRA:3XV) ("XVIVO" or "the Company") has entered into an agreement to acquire the transplant clinical workflow automation business, which includes, among other things, the development and distribution of the FlowHawkTM software platform, from Healthtech Solutions Inc. dba OmniLife. Organ transplantation is a complex, life-dependent process where flawless communication, both internal and external, is critical for transplant centers and the transplant ecosystem. With the acquisition of FlowHawk, XVIVO strengthens its service offering in the US, making planning and communication throughout the transplant process easier for its customers.

The increasingly complex and rapidly changing transplant system in the US requires new tools and support systems to better enable transplant teams to manage critical activities throughout the transplant process. Today, transplant centers often need to rely on traditional text messages, emails, and phone calls for communication - which may be highly burdensome and inefficient. Transplant centers need ways to lower barriers and streamline processes to continue increasing the number of transplant procedures. The FlowHawk software allows for direct HIPAA-compliant communication with relevant teams, ensuring the right information is delivered to the right people at the right time. Easy, transparent, and traceable workflows ensure that all relevant tasks are completed and decisions are logged.

Through the acquisition, XVIVO is building for the future. The FlowHawk software has an established footprint among leading transplant centers in the US and XVIVO feels confident in making the solution available to many more transplant centers, building on the already proven commercial success of OmniLife. XVIVO expects the acquisition to positively affect its service revenue in the US and FlowHawk will play a central part in the beyond product offering.

"One of our strategic focus areas is to become the preferred partner in the transplant process, and this acquisition brings us closer to that goal. Our organ recovery service in the US is already using FlowHawk and we are very eager to offer this solution to more customers. We share a common goal with our customers: more patients must receive the transplants they desperately need. To achieve this, we must support transplant centers with services that reduce obstacles. Our vision is clear: ‘No one should die waiting for a new organ'," says Christoffer Rosenblad, CEO of XVIVO.